Windtree Therapeutics (WINT) AI Stock Analysis

Windtree Therapeutics

(Other OTC:WINT)

Select Model

Rating:42Neutral

Price Target:$0.01▲(2066.67% Upside)

Action:upgraded

Date:02/04/26

Windtree Therapeutics is in a precarious financial position, with negative equity, persistent cash burn, and minimal revenue. The stock is in a strong downtrend and is technically oversold but remains under pressure. Valuation metrics are unattractive, and recent executive turnover further clouds the outlook. The overall score of 42 reflects a high-risk investment with substantial downside potential.

Positive Factors

Focused critical-care biotech pipelineSpecialization in critical‑care and cardiopulmonary therapeutics is a durable strategic position: these are high‑unmet‑need areas with structural demand and limited crowded competition. A successful clinical advance could produce outsized long‑term returns relative to company size.

Negative Factors

Negative equity and rising leverageNegative equity and increased debt signal materially impaired balance‑sheet resilience. With equity deficit and higher leverage, the company faces elevated insolvency, refinancing and dilution risks, reducing financial flexibility to fund clinical programs long term.

Windtree Therapeutics (WINT) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $20.23K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.0
Beta (1Y): 2.12
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Windtree Therapeutics Business Overview & Revenue Model

Company Description

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime,...

How the Company Makes Money

null

Windtree Therapeutics Financial Statement Overview

Summary

Income statement shows first revenue but deep losses (score 8/100). Balance sheet indicates negative equity and solvency concerns (4/100). Cash flow remains negative with high burn (7/100). After converting to the rating scale, the composite financial performance score is 41, reflecting significant distress and high financial risk.

Income Statement

8Very Negative

Balance Sheet

4Very Negative

Cash Flow

7Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Dec 2020
Income Statement
Total Revenue	90.00K	0	0	0	0	0
Gross Profit	11.00K	-84.00K	-82.00K	-1.06M	-869.00K	-638.00K
EBITDA	-42.60M	-1.47M	-20.16M	-39.99M	-77.32M	-32.27M
Net Income	-40.00M	-5.49M	-20.29M	-39.21M	-67.64M	-30.28M
Balance Sheet
Total Assets	15.98M	27.88M	32.41M	37.95M	74.79M	112.89M
Cash, Cash Equivalents and Short-Term Investments	204.00K	1.78M	4.32M	6.17M	22.35M	16.93M
Total Debt	12.93M	1.82M	16.83M	2.28M	2.89M	3.78M
Total Liabilities	27.58M	17.88M	29.02M	27.94M	32.91M	43.33M
Stockholders Equity	-11.61M	10.00M	3.39M	10.01M	41.88M	69.55M
Cash Flow
Free Cash Flow	-15.12M	-15.41M	-13.45M	-19.46M	-23.94M	-25.61M
Operating Cash Flow	-15.12M	-15.40M	-13.44M	-19.45M	-23.66M	-25.32M
Investing Cash Flow	-5.97M	-12.00K	-15.00K	197.00K	-279.00K	-291.00K
Financing Cash Flow	19.00M	12.73M	11.60M	3.08M	29.36M	19.96M

Windtree Therapeutics Technical Analysis

Technical Analysis SentimentNegative

Last Price0.00

Price Trends

50DMA0.01Negative

100DMA0.01Negative

200DMA0.04Negative

Market Momentum

MACD-0.00Positive

RSI45.18Neutral

STOCH-38.89Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 0.00 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.18 is Neutral, neither overbought nor oversold. The STOCH value of -38.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.

Windtree Therapeutics Risk Analysis

Windtree Therapeutics disclosed 83 risk factors in its most recent earnings report. Windtree Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.As a result of our failure to timely file this Quarterly Report with the SEC, we are currently ineligible to file new registration statements on Form S-3, which may impair our ability to raise capital in a timely manner or at all.Q3, 2024

2.Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations in the near term.Q3, 2024

Windtree Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

WINT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDP	51Neutral	$474.57M	-0.44	-302.75%	―	―	81.43%
TOVX	43Neutral	$7.82M	-0.26	-93.49%	―	―	94.38%
AZTR	42Neutral	$4.66M	-0.06	-205.45%	―	―	78.16%
WINT	42Neutral	$26.99K	0.00	967.64%	―	―	―
ARTL	40Underperform	$1.22M	-0.03	-519.09%	―	―	59.79%
ENVB	26Underperform	$6.40M	-0.09	-168.05%	―	―	87.05%

* Healthcare Sector Average

Performance Comparison

WINT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
WINT	Windtree Therapeutics Inc	0.01	-0.08	-88.89%
TOVX	Theriva Biologics, Inc.	0.17	-0.15	-47.69%
INDP	Indaptus Therapeutics, Inc.	3.09	-0.03	-0.96%
ENVB	Enveric Biosciences, Inc.	1.43	-5.65	-79.80%
ARTL	Artelo Biosciences	2.22	-78.78	-97.26%
AZTR	Azitra Inc	0.77	-4.14	-84.35%

Windtree Therapeutics Corporate Events

Business Operations and StrategyM&A Transactions

Windtree Therapeutics Sells Cardiovascular Portfolio, Retains Upside

Positive

Jul 22, 2026

On December 16, 2025, Windtree Therapeutics signed an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC, with closing effected the same day. Windtree will retain an economic interest through entitlement to...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Feb 04, 2026

Windtree Therapeutics AI Stock Analysis